NCT03318939 2024-04-03
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
Clinical Trials
4 trialsNCT02659514 2022-03-11
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02418689 2022-01-20
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT04044170 2020-11-17
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Hanmi Pharmaceutical Company Limited
Phase 2 Terminated